Cancer Moonshot - inmunoterapia

Foro general ciencia, medicina, nutrición, salud pública, política

Moderador: Fisio

Avatar de Usuario
Fisio
Administrador del Sitio
Mensajes: 6733
Registrado: Dom, 01 Sep 2013, 14:18
Ubicación: foromuscleblog@gmail.com

Jue, 25 May 2017, 19:26

Calentando un tumor con oncovirus. Cancer que no responde a inhibidores de checkpoint comienzan a hacerlo cuando se les trata con oncovirus
combined treatment with adenoviral p53 (Ad-p53) or adenoviral IL-24 (Ad-IL24) and anti-PD-1 reversed anti-PD-1 resistance demonstrating even greater therapeutic efficacy with synergistic decreases in tumor size and increased survival.
http://www.prnewswire.com/news-releases ... 60393.html
Avatar de Usuario
Fisio
Administrador del Sitio
Mensajes: 6733
Registrado: Dom, 01 Sep 2013, 14:18
Ubicación: foromuscleblog@gmail.com

Dom, 04 Jun 2017, 22:16

El cancer inhibe las señales de dolor via PD-L1 para ocultarse

https://immuno-oncologynews.com/2017/05 ... -its-pain/


Tremendo.
Avatar de Usuario
Fisio
Administrador del Sitio
Mensajes: 6733
Registrado: Dom, 01 Sep 2013, 14:18
Ubicación: foromuscleblog@gmail.com

Sab, 10 Jun 2017, 00:13

Vacuna con citomegalovirus muy prometedora en glioblastoma.
The team from Duke University Medical Center in Durham, North Carolina, USA, explains that CMV proteins have been detected in over 90% of sampled glioblastomas, with the expression restricted to glioma cells, providing “an unparalleled opportunity to subvert cytomegalovirus antigens as tumor-specific targets.”

All 11 patients who completed three vaccine courses had better survival than that predicted by the recursive partitioning analysis classification, with a median gain of 30 months, John Sampson and co-researchers report.

Improvement in survival occurred despite an increase in the proportion and proliferation of regulatory T cells after the first DI-TMZ cycle.

https://www.medwirenews.com/neuro-oncol ... b/12245322
Avatar de Usuario
Fisio
Administrador del Sitio
Mensajes: 6733
Registrado: Dom, 01 Sep 2013, 14:18
Ubicación: foromuscleblog@gmail.com

Sab, 10 Jun 2017, 00:24

MMR se convertirá en firma para tratamiento con inhibidores de checkpoint, independientemente del cancer

https://www.aaas.org/news/studies-open- ... r-patients
Avatar de Usuario
Fisio
Administrador del Sitio
Mensajes: 6733
Registrado: Dom, 01 Sep 2013, 14:18
Ubicación: foromuscleblog@gmail.com

Sab, 10 Jun 2017, 00:26

Sinergias a inhibidores de checkpoint: IDO
IDO, which starves immune cells by breaking down the crucial amino acid tryptophan. IDO can suppress immune responses and rein in potentially damaging inflammation.
http://www.nature.com/news/next-generat ... es-1.22092
Avatar de Usuario
Fisio
Administrador del Sitio
Mensajes: 6733
Registrado: Dom, 01 Sep 2013, 14:18
Ubicación: foromuscleblog@gmail.com

Sab, 10 Jun 2017, 00:29

Combinación de tratamientos en carcinoma de Merkel. Mucha esperanza aquí. Recuerda al cisplatín en los 70s... desde su inicio, hasta que se aprendió a usar.
The trial combined a form of T-cell therapy; a newly FDA-approved immunotherapy drug known as avelumab, a checkpoint inhibitor drug made by EMD Serono; and either radiation or interferon
All four patients who received this triple therapy saw their cancer shrink in response; three of them are now in what's known as complete remission, where biopsies of their tumor sites show no evidence of remaining cancer cells. The researchers have followed the patients for a median of 12 months since the start of the trial.
https://scienmag.com/triple-immunothera ... age-trial/
Avatar de Usuario
Fisio
Administrador del Sitio
Mensajes: 6733
Registrado: Dom, 01 Sep 2013, 14:18
Ubicación: foromuscleblog@gmail.com

Sab, 10 Jun 2017, 00:33

765 estudios de combinaciones en marcha a día de hoy.
765 combination studies listed on clinicaltrials.gov. Keytruda leads the pack, with 268 — up from 70 just 18 months ago. For Bristol-Myers it’s 242, more than three times the number EP Vantage’s editorial team found in 2015.
https://endpts.com/checkpoint-combos-fo ... es-report/


Como estaba la cosa hace 2 años, y como está ahora.


Imagen
Avatar de Usuario
Fisio
Administrador del Sitio
Mensajes: 6733
Registrado: Dom, 01 Sep 2013, 14:18
Ubicación: foromuscleblog@gmail.com

Mié, 14 Jun 2017, 21:16

Los chinos en acción por fin con un VEGFR
Fruquintinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor

https://jhoonline.biomedcentral.com/art ... 016-0384-9
Avatar de Usuario
Fisio
Administrador del Sitio
Mensajes: 6733
Registrado: Dom, 01 Sep 2013, 14:18
Ubicación: foromuscleblog@gmail.com

Vie, 16 Jun 2017, 03:54

Targeting T-reg cells via neurolipina 1...
Vignali and his colleagues discovered that a surface protein called neuropilin-1 (Nrp1), which is expressed on almost all Tregs that infiltrated mouse tumors, was required to maintain the function, integrity and survival of Tregs within the harsh tumor microenvironment. Thus, Nrp1 on Tregs helps suppress the body's natural anti-tumor immune response thereby helping the tumor survive. Importantly, blocking or deleting Nrp1 in Tregs in mice only impacted their function in tumors and not in the rest of the body, resulting in tumor eradication without inducing autoimmune or inflammatory disease.

"What we've shown in the current study is that in mice, Nrp1 expression by Tregs is required to maintain their ability to prevent the immune system from clearing the tumor. Interestingly, when Tregs lose Nrp1, they not only fail to suppress, they also become active participants in the anti-tumor immune response," said Vignali. "Intriguingly, we also found that in cancer patients who had a poor prognosis, the Nrp1-expressing Treg subset was much higher, suggesting that the findings could apply to humans as well."
https://medicalxpress.com/news/2017-06- ... erapy.html
Avatar de Usuario
Fisio
Administrador del Sitio
Mensajes: 6733
Registrado: Dom, 01 Sep 2013, 14:18
Ubicación: foromuscleblog@gmail.com

Vie, 16 Jun 2017, 03:56

PD-L2 predice respuesta a inhibidores de checkpoint, independientemente de la expresión de PD-1
altered PD-L2 expression may do better when treated with PD-1 targeting immunotherapy regardless of their levels of PD-L1, which is the current biomarker of choice for this class of drugs.
https://www.genomeweb.com/molecular-dia ... erck-study
Responder